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Abstract: Immunoglobulin G (IgG) molecules are glycoproteins and residues in the sugar moiety attached
to the IgG constant fragment (Fc) are essential for IgG functionality such as binding to cellular Fc
receptors and complement activation. The core of this sugar moiety consists of a bi-antennary heptameric
structure of mannose and N-acetylglucosamine (GlcNAc), further decorated with terminal and branching
residues including galactose, sialic acid, fucose, and GlcNAc. Presence or absence of distinct residues such
as fucose and sialic acid can dramatically alter pro- and anti-inflammatory IgG activities which could be
harnessed for immunotherapeutic purposes. Here we review recent advances in understanding the role
of the IgG-Fc glycan during immune responses and for immunotherapy with a focus on sialic acid and
intravenous immunoglobulin (IVIG) treatment.
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Abstract Immunoglobulin G (IgG) molecules are glycopro-
teins and residues in the sugar moiety attached to the IgG
constant fragment (Fc) are essential for IgG functionality such
as binding to cellular Fc receptors and complement activation.
The core of this sugar moiety consists of a bi-antennary
heptameric structure of mannose and N-acetylglucosamine
(GlcNAc), further decorated with terminal and branching
residues including galactose, sialic acid, fucose, and
GlcNAc. Presence or absence of distinct residues such as
fucose and sialic acid can dramatically alter pro- and anti-
inflammatory IgG activities which could be harnessed for
immunotherapeutic purposes. Here we review recent ad-
vances in understanding the role of the IgG-Fc glycan during
immune responses and for immunotherapy with a focus on
sialic acid and intravenous immunoglobulin (IVIG) treatment.
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Immunoglobulin G Effector Functions
Immunoglobulins belong to the most abundant proteins found
in serum [3]. Producing these vast amounts of proteins is a
huge investment of the body with good cause: Antibodies are
an essential component of the immune system bridging hu-
moral and cellular immunity to fulfill inflammatory (assisting
the killing of infected cells or tumor cells), non-inflammatory
(obsonization, neutralization) and, as most recently recog-
nized, also anti-inflammatory functions. Immunoglobulin G
(IgG) represents 75 % of the immunoglobulins in serum
reflecting its role in defending us against bacteria and viruses
which have penetrated epithelial and mucosal barriers [1].
During a primary infection and if innate immunity and pre-
existing low-affinity antibodies (natural antibodies) fail to
neutralize the pathogen, immunoglobulins increase the visi-
bility of the pathogen or the infected cell through opsonization
and initiate immune responses through binding to cellular
receptors specific for the antibodies’ Fc region (Fcγ receptors;
FcγRs) and the activation of the complement system. This
activates phagocytes such as macrophages and dendritic cells
which engulf, destroy, process and transport the pathogen to
secondary lymphoid organs for the initiation of a protective
adaptive immune response. Furthermore, infected cells can be
lysed by a mechanism called “antibody-dependent cell medi-
ated cytotoxicity” (ADCC) by which FcγR-receptor bearing
innate immune cells such as natural killer cells lyse antibody-
opsonized cells [53]. Similar to Fc-receptor expressing cells,
the complement system uses antibodies as specific detectors to
fulfill its dual role in both eradicating pathogens and infected
cells by complement-dependent cytotoxicity (CDC) and si-
multaneously assisting their uptake by phagocytes for antigen
presentation [1]. The four different subclasses of IgG mole-
cules differ in their efficacy to initiate immune cell activation
through FcγR binding and complement activation.
The IgG-Fc N-Glycan
Immunoglobulin G (IgG) molecules are glycoproteins with a
sugar moiety attached to each of the asparagin 297 (N297)
residues in the CH2-domains of the two Fc-fragments (Fig. 1).
Removal of this sugar moiety impairs Fc-dependent effector
functions [14, 38]. All human immunoglobulins are Fc-
glycosylated and can, depending on the isotype and the se-
quence of the antigen-binding regions (complementary deter-
mining regions, CDR), carry additional glycans in the Fab
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domains. IgG is unique with respect to a single, highly con-
served Asparagine(N)-Glycosylation site (N-X-S/T) in the
CH2 domains while the isotypes carry multiple glycosylation
sites [7]. Moreover, in contrast to other Ig isotypes, the IgG-
associated sugar domain is not exposed on the IgG surface but
rather buried within the hydrophobic core between the two Fc-
fragments and, therefore, impacts Fc-structure [30, 36].
During protein translation a pre-formed lipid-linked glycan
is transfered and covalently attached to asparagine at position
297 in the lumen of the endoplasmatic reticulum (ER). This
initial glycan is composed of two N-acetylglucosamines
(GlcNAc) followed by branched mannose (Man) residues.
Its structure is highly conserved in eukaryotes and serves as
an important mechanism for protein folding and quality con-
trol of proteins carrying N-glycans [48]. If successfully pro-
duced and folded, the IgG polypeptide is transfered from the
ER to the Golgi where glycosyl-hydrolases and -transferases
can modify the core glycan leading to such diverse and highly
complex glycans as seen in the IgG-Fc. The monosaccharide
composition of the glycan is impacted by the amino-acid
sequence [29] as well as glycan modifying enzyme- and
substrate availability. The presence of glycosylhydrolases
and glycosyltransferases in the golgi can be regulated at the
level of transcription and location within the secretory path-
way [43]. Peptide-glycan interactions and the three-
dimensional structure of the Fc are thought to limit the glycan
variability and the extent of galactosylation and sialylation by
limiting the accessability of the glycan to glycosyltransferases
[29, 57]. A total of around 30 different glycan structures is
found in the IgG-Fc pool [41]. Compared to the Fab glycans,
reduced bisecting GlcNAc, less galactose and less sialylation
is found on the Fc glycans [57]. The restricted diversity may
be essential for the use of specific IgG-Fc glycan modification
for the regulation of antibody effector functions. How and
which immunological factors such as cytokines influence
antibody glycosylation is yet to be defined but much progress
has been made in understanding the structural and functional
consequences of the presence or absence of different sugar
moieties on the IgG-Fc carbohydrate. In addition to the oligo-
saccharide core, more than 95 % of the biantennary complex
type structure of the final IgG glycan carries a N-
acetylglucosamine on both arms [40, 41] and 85 % are
fucosylated [34] (Fig. 1). In contrast, the presence of galactose
is less homogenous with 40 % of glycans carrying one galac-
tose (G1 glycan) and the frequency of non-galactosylated
(G0) or bi-galactosylated glycans (G2) ranging between 20
and 40 % depending on age and gender [40, 51]. Additional
heterogeneity is conferred by the addition of a bisecting N-
acetylglucosamine present on approximately 10 to 15 % of
total IgG-Fc glycans [58].
Based on the structure of the glycan, the conformation of the
IgG-Fc homodimer in the binding interface to Fc-receptors and
the complement protein C1q (CH2 domain) changes from an
open (maximal C2-C2 domain distance) to a closed conforma-
tion (minimal C2-C2 domain distance) [16, 33]. Analysis of
crystal structures revealed that removal of terminal galactose
and N-acetylglucosamine residues favours a closed conforma-
tion which in turn disfavours Fc-receptor and C1q binding and
impacts on the thermal stability [28, 32, 33]. The most distal
sugar on the glycan is sialic acid (neuraminic acid, Neu5Ac).
Around 10 % of glycans carry sialic acid on one arm and bi-
sialylated glycans are found only in trace amounts. The linkage
of sialic acid to the penultimate galactose is found in either α2-
3 or α2-6 confirmation with a strong preference for the latter
[7]. Addition of galactose has a strong preference for the 1–6
arm, whereas sialic acid is almost exclusively found on the 1–3
arm [57]. While the 1–6 arm bias of galactose may be largely
explained by accessability [57] the 1–3 arm specific addition of
sialic acid by human sialyltransferase is retained even in vitro
using the released Fc glycan, substrate and recombinant human
sialyltransferase arguing for an enzyme-intrinsic bias [8]. The
opposing glycan arm-bias of galactose and sialic acid provides
Fig. 1 IgG-Fc glycan structure. The Asparagine 297 linked complex-
type glycan found on the Fc domain of immunoglobulin G antibodies
consists of a set of constant (depicted bold) and variable (depicted regular)
sugars. Although theoretically possible, this fully processed glycan will
be found only in trace amounts as the majority of antibodies will carry
either no, one or two galactose residues and a fraction of those carrying
galactose will additionally possess sialic acid. Further complexity is
added by the addition of the bisecting N-acetylglucosamine. Man Man-
nose, Neu5Ac Neuraminic acid (Sialic acid), Gal Galactose, GlcNAc N-
acetylglucosamine, Fuc Fucose, N Asparagine
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a rationale for the inefficient addition of sialic acid. The func-
tional consequence of sialylation may be reduced FcγR bind-
ing [45] and enhancing the anti-inflammatory properties of IgG
molecules [6] as discussed below.
Function of Fc N-glycan Fucose-Residues
The majority of circulating IgG is fucosylated [34], which has
been shown to reduce the binding to the activating FcγRIII
(CD16) and consequently antibody-dependent cell mediated
cytotoxicity [50]. Direct carbohydrate-carbohydrate interac-
tions between the FcγRIII Asn162 linked glycan and the Fc
glycan are responsible for this effect [15]. The in vivo rele-
vance of increased antibody binding to CD16 was first indi-
cated in patients carrying a high affinity receptor polymor-
phism which increased the efficacy of the B cell depleting
antibody Rituximab [10]. Similarly, clinical trials using non-
fucosylated antibodies for cell depletion therapy in cancer
have shown promising results [24, 37]. Largely reduced levels
of fucosylated IgG have been reported on alloantigen-specific
(anti-HPA1a) antibodies in neonatal alloimmune thrombocy-
topenia (FNAIT) in contrast to normal levels in the total
antibody pool suggesting specific regulation of fucosylation
and a potential role in autoimmunity [26].
Function of Fc N-glycan Galactose-Residues
The absence of galactose in the core glycan (IgG-G0) has long
been known to be associated with rheumatoid arthritis (RA)
and primary osteoarthritis [41]. Similar observations were
made in other autoimmune diseases, infectious diseases and
cancer [20, 49]. The first suggested mechanism for a functional
consequence of galactosylation was based on the in vitro find-
ing that galactosylation prevents binding of the initiator of the
lectin pathway of the complement system, mannose binding
lectin (MBL) [31]. However, in vivo studies in mouse models
could not confirm a role of MBL for the function of
agalactosylated antibodies [35] and analysis of patients carry-
ing MBL promotor polymorphisms leading to differential
MBL expression level could not find a role for MBL in RA
[55, 56]. A dual role for MBL was found in juvenile RAwhere
MBL deficiency led to younger age of juvenile polyarthritis
onset but more frequent remission of juvenile oligoarthritis
[13]. A recent study in mice shows that antibody
galactosylation can contribute to limiting anaphylatoxin C5a
mediated complement-activation by a mechanism involving
Dectin-1 and FcγRIIb dependent inhibition of C5a receptor
signaling [27]. The observation that antiviral activity and spon-
taneous control of HIV infection is associated with increased
prevalence of total and in particular antigen-specific IgG-G0
antibodies additionally argues for a functional significance of
antibody galactosylation in humans [2]. An important aspect to
consider when looking at the functional impact of galactose is
that it provides the basis for the addition of sialic acid, the most
distal sugar moiety on the IgG-Fc glycan.
Function of Fc N-glycan Sialic Acid-Residues
In mice, T cell independent B cell activation or tolerogenic
immunization (in the absence of pro-inflammatory stimuli)
with protein antigens induces antigen-specific IgG with high
levels of terminal galactose and sialic acid capable of blocking
antigen-specific B and T cell responses [19, 39]. Similarly,
successful treatment of birch pollen allergy was found to
induce antigen-specific IgG partially carrying sialic acid
[39]. The mechanisms that mediate such anti-inflammatory
properties are not yet clear but may involve reduced binding to
Fc receptors [25] or sialic acid binding lectins such as DC-
SIGN [4].
The Role of IgG Fc-glycosylation for IVIG Treatment
of Autoimmunity
The anti-inflammatory effect of pooled high-dose
gammaglobulins from healthy donors infused in patients (so-
called intravenous immunoglobulin, IVIG) suffering from
autoimmune diseases was first recognized during immuno-
globulin replacement therapy of a patient suffering
hypogammaglobulinemia and immune thrombocytopenia
(ITP) [21–23]. Subsequently, IVIG has been approved for
the treatment of the autoimmune diseases ITP, Kawasaki’s
disease, chronic inflammatory demyelinating polyneuropathy
(CIDP) and multifocal motor neuropathy but is used for many
other neuromuscular, hematologic or dermatologic disorders
[17]. Numerous mechanisms for the anti-inflammatory action
of IVIG have been suggested. Examples therefore are ranging
from increased clearance of pathologic antibodies due to the
saturation of the neonatal Fc-receptor [18], anti-idiotypic an-
tibodies [52] and suppression of dendritic cell maturation [9]
to the activation of regulatory T cells via Fc-derived peptides
[11]. Studies in mouse models [5, 44] and humans [12] clearly
point towards a major role for the IgG-Fc for the anti-
inflammatory properties of IVIG. Because an extremely high
dose of IVIG is required for its efficacy (1–2 g per kg), it was
speculated that the beneficial effect may be mediated by a
small sub-fraction of IVIG. Ravetch and colleagues identified
sialylated Fc fragments as the anti-inflammatory mediator of
IVIG in the K/N experimental arthritis mouse model [5, 25].
Subsequent studies implicated a protective mechanism in-
volving the inhibitory Fc receptor (FcγRIIb) and the C-type
lectin SIGNR1 or its human ortholog DC-SIGN [4, 46].
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Signaling downstream of DC-SIGN was found to induce IL-
33 which in turn induces IL-4 in basophils leading to the
upregulation of FcγRIIb on macrophages [4]. The require-
ment of sialic acid and FcγRIIb has been recently confirmed
in four mouse models of antibody-mediated autoimmune
diseases whereas SIGNR1 was not always required [47].
Although the relevance of DC-SIGN (or SIGNR1) for the
initiation of a sialic-acid specific response is supported by
several studies [4, 5, 46], it remains unclear whether direct
binding of Fc-linked sialic acid to these receptors [6] is man-
datory as no binding of IgG-Fc (independent of its glycosyl-
ation) to DC-SIGN was detected by others [59].
Studies in humans support a role for FcγRIIb expression as
being associated with the clinical efficacy of IVIG therapy.
Chronic inflammatory demyelinating polyneuropathy (CIDP)
is themost common treatable acquired chronic polyneuropathy,
and IVIG is widely used as a first-line initial and maintenance
treatment. Untreated patients with CIDP, compared with demo-
graphically matched healthy controls, showed consistently
lower FcγRIIb expression levels. FcγRIIb expression was,
however, up-regulated on circulating monocytes and B cells
after clinically effective IVIG therapy [54]. Preliminary data
from our laboratory suggest that the frequency of sialic acid-
containing IgG Fc-glycoforms is associated with disease remis-
sion (unpublished observation).
Thus, there is accumulating evidence that both FcγRIIb
and sialic acid play a major role for the anti-inflammatory
effect of IVIG but depending on the experimental conditions,
other yet to be defined mechanisms might have additional Fc-
glycan and FcγRIIb-independent effects. It is important to
consider that all available data on the requirement of sialic
acid for IVIG efficacy have been generated in mouse models
infused with human IVIG (or modified derivatives thereof).
Furthermore, all animal models that show a dependency on
sialic acid involve the transfer of serum or pathogenic auto-
antibodies [4, 25, 46, 47], whereas expansion of protective
regulatory T cells as well as augmentation of their effector
function during HSV-induced encephalitis was found to be
independent of sialylation [42]. Studies in humans and com-
plementary humanized animal models are, therefore, manda-
tory to better define the role of Fc-glycosylation and the
requirements for anti-inflammatory IgG activity.
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